Vascular endothelial growth factor (VEGF) is an angiogenic factor shown to be a critical
secreted cytokine in tumorigenesis and retinal neovascularization (NV). Currently, there are
two anti-VEGF agents, pegaptanib and ranizumab, approved by the United States Food and
Drug Administration (FDA) for intravitreal use in the treatment of wet age-related macular
degeneration (AMD). Bevacizumab is FDA-approved for intravenous administration in the
treatment of several cancers and is in widespread use, off-label, as an intravitreal injection to …